Cumulative incidence curves depicting the diagnosis of hematologic malignancy from time of diabetes mellitus diagnosis in GLP-1 RA and SGLT2 inhibitor users are shown in Figs. 2 and 3. This evidence concerns the gene GCG and diabetes mellitus.